WHY O	100	آ ک							Sheet	1 of 2
Q IMAD				ENT OF COMMERCE TRADEMARK OFFICE		ATTY. DOCKET NO. 2710-4007 US		SERIAL NO. 09/302,896		
INF	ORM	ATI	ON DISCLOSU	RE CITAT	ION	M. B. CHANCE	LLOR and J.	HUARD		
(Use several sheets if necessary)						FILING DATE April 30, 1999	group at 1 643	GROUP ART UNIT 1643 / (36		
				U.S.	PATENT I	DOCUMENTS				
EXAMINER INITIAL		D	OCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS		G DATE OPRIATE
R	1	5,	594,032	1/14/97	Gonzalez-Cadavid et al.		514	645	;	
				FOREIC	EN PATEN	T DOCUMENT	S			
			OCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANS	LATION
	2 2		OCOMENT NOMBER	DATE	COUNTRY			_	YES	NO
2	2	W	O 98/36055	20/8/98	PCT					ļ
82	3	W	O 96/18303	20/6/86	PCT		/			
&	4	W	O 99/47163	23/9/99	PCT					
		O	THER DOCUM	IENTS (Inc	luding Auth	or, Title, Date, I	Pertinent F	Papers, Etc.)		
A		5	M. Reza Dana and Promotes 39:70-77.	et al., "Inte Ocular Immi	erleukin-1 R une Privileg	eceptor Antagoni e", <u>Investigative</u>	st Suppres Ophthalm	sses Langerha nology & Visi	ns Cell Acual Science	ctivity <u>s,</u> 1998,
Sa		6	G. Ferrari et al., "Muscle Regeneration by Bone Marrow-Derived Myogenic Progenitors", Science, 1998, 279:1528-1530.							
S		7	E. Barr and J. Leiden, "Systemic Delivery of Recombinant Proteins by Genetically Modified Myoblasts", Science, 1991, 254:1507-1509.							
Se		8	T. Katagiri et al., "Bone Morphogenetic Protein-2 Converts the Differentiation Pathway of C2C12 Myoblasts into the Osteoblast Lineage", J. Cell Biology, 1994, 127:1755-1766.							
Se		9				ouse Myoblast P e Therapy", J. C				7.
									•	
EXAMINE	R		fush.	1	D	ATE CONSIDE	RED	17221	14	
EXAMINE through cita	R: In tion i	itial f not	if reference cons in conformance	idered, whe	ther or not sidered. In	citation is in conf clude copy of thi	ormance v s form wit	with MPEP 60 h next comm	09; Draw i	line to

applicant.

E,	Mirr	Ä						Sheet 2 of 2		
FORM PTO-	TO THA	PATENT AND T	ENT OF COM		ATTY. DOCKET NO. 2710-4007 US	1	SERIAL N 09/302			
INFO	RMATI	ON DISCLOSU	RE CITATIO	ON	APPLICANT M. B. CHANCEL	LOR and J. I	HUARD			
	(Use se	everal sheets if no	ecessary)		FILING DATE April 30, 1999			GROUP ART UNIT 1643 636		
			U.S. P.	ATENT D	OCUMENTS					
EXAMINER INITIAL	DX	OCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
			FOREIGN	N PATEN	r document:	<u> </u>				
	bo	OCUMENT NUMBER	DATE	c	OUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO		
	0	THER DOCUM	IENTS (Inclu	ding Autho	or, Title, Date, F	ertinent Pa	apers, Etc.)			
æ	10	Adenovirus Tr	ansfected with	Human I	s a Potential Treanductible Nitric (upplement:305 (A	Oxide Synt	hase (iNOS)	on of Myoblast- into the Proxima		
٤	11	J. Huard et al., Detrusor Contr 1998, 159 (5) S	actility and C	ell-Mediat	ed Gene Therapy	all: A Poss for Bladd	sible Metho er Dysfunct	d of Modulating ion", <u>J. Urology</u> ,		
٤	J. Huard et al., "Nitric Oxide Synthase (NOS) Gene Therapy for Erectile Dysfunction; Comparison Between Plasmid, Adenovirus and Adenovirus Transduced Myoblast Vectors", <u>J. Urology</u> , 1998, 159:90 (Abstract 342).									
	_	·		·						
			······································							
EXAMINER		LA	1	DA	TE CONSIDER	RED	1/22/24	io		
EXAMINER:	Initial on if not	if reference cons	idered, wheth	er or not c	itation is in confe	ormance w	ith MPEP 6	09; Draw line		

applicant.